Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;62(2):112-119.
doi: 10.5468/ogs.2019.62.2.112. Epub 2019 Mar 4.

Effects of cisplatin on photosensitizer-mediated photodynamic therapy in breast tumor-bearing nude mice

Tae-Gyu Ahn  1 , Ji Min Jung  1 , Eun-Jeong Lee  1 , Ji Hyun Choi  1
Affiliations

Effects of cisplatin on photosensitizer-mediated photodynamic therapy in breast tumor-bearing nude mice

Tae-Gyu Ahn et al. Obstet Gynecol Sci. 2019 Mar.

Abstract

Objective: This study aimed to evaluate the potential effects of cisplatin on photodynamic therapy (PDT) in breast cancer using a breast tumor-bearing mouse model.

Methods: In this study, breast tumor (experimental mammary tumour-6 cell)-bearing nude mice were used as experimental animals. Photolon® (photosensitizer, 2.5 mg/kg body weight [BW]) was injected intraperitoneally; after 2 hours, the tumors were irradiated (660 nm, 80 J/cm2) using a diode laser tool. Cisplatin (3 mg/kg BW) was injected intraperitoneally 1 hour before the Photolon® injection.

Results: Tumor volume increased over time in the control group and was not different from that in the cisplatin group. In the PDT group, the tumor volume increased on day 3, but not on day 7. In the cisplatin+PDT group, tumor volume increased on day 3 but decreased on day 7. There was no significant difference in the levels of thiobarbituric acid reactive substance (TBARS) in tumor tissues between the control and cisplatin groups. The levels of TBARS in the cisplatin+PDT group were higher (47%) than those in the PDT group. Analysis of tumor tissue transcriptomes showed that the expression of genes related to the inflammatory response including CL and XCL genes increased, while that of Fn1 decreased in the cisplatin+PDT group compared with the PDT group.

Conclusion: These results suggest that cisplatin enhances the therapeutic effect of PDT in a breast tumor-bearing mouse model. However, further clinical studies involving patients with breast cancer is needed.

Keywords: Breast cancer; Cisplatin; Nude mice; Photodynamic therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Photograph of breast tumor-bearing mice after PDT. Diode lazer light (660 nm, 80 J/cm2) was used to irradiate the tumor mass of mice 2 hours after intra-peritoneal injection of Photolon® (2.5 mg/kg). Cisplatin (3 mg/kg) was injected intraperitoneally 1 hour before Photolon® treatment.
PDT, photodynamic therapy.
Fig. 2
Fig. 2. TBARS in tumor tissue of tumor-bearing mice after treatment with PDT. TBARS contents in tumor tissue of tumor bearingmice were measured 24 hours after PDT using OxiSelect™ TBARS assay kit. Data were analyzed using Duncan's multiple range test.
TBARS, thiobarbituric acid reactive substance; PDT, photodynamic therapy.
See this image and copyright information in PMC

References

    1. McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ. Effects of age on the detection and management of breast cancer. Cancers (Basel) 2015;7:908–929. - PMC - PubMed
    1. Mangla B, Kohli K. Combination of natural agent with synthetic drug for the breast cancer therapy. Int J Drug Dev Res. 2018;10:22–26.
    1. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61:250–281. - PMC - PubMed
    1. Silva JN, Filipe P, Morlière P, Mazière JC, Freitas JP, Cirne de Castro JL, et al. Photodynamic therapies: principles and present medical applications. Biomed Mater Eng. 2006;16:S147–54. - PubMed
    1. O'Connor AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol. 2009;85:1053–1074. - PubMed